Chief Medical Officer, Inotek Pharmaceuticals Corporation (small molecule PARP inhibitors), responsible for clinical development strategy and global clinical operations
Vice President, Intercontinental Clinical Development and Chair, Product realization protocol review committee, Aventis (now Sanofi-Aventis), responsible for worldwide review across eight therapeutic areas (oncology, CV, diabetes, anti-infectives, CNS, asthma, bone metabolism, rheumatology)
Group Director, Outcomes Research, Director of Cardiovascular Clinical Research, Bristol-Myers Squibb.
MD, Temple University; PhD, Physiology, Thomas Jefferson University; MS Physiology, University of Illinois; MS Biomedical Engineering, Drexel University
